Search
De Novo Triacylglycerol Biosynthesis TG(20:0/20:0/i-20:0)
smpdb.ca/view/SMP0033792MetabolicA triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...
Cardiolipin Biosynthesis CL(12:0/20:0/20:0/i-20:0)
smpdb.ca/view/SMP0191473MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(14:0/20:0/20:0/i-20:0)
smpdb.ca/view/SMP0201592MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(16:0/20:0/20:0/i-20:0)
smpdb.ca/view/SMP0206920MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-13:0/20:0/20:0/20:0)
smpdb.ca/view/SMP0246177MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-15:0/20:0/20:0/20:0)
smpdb.ca/view/SMP0246335MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.
Trimetrexate
go.drugbank.com/drugs/DB01157ApprovedIt is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[L40298] In September 2022, Skysona was approved by the FDA.[L43247] … It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.
International brands: Lenti-DTilbroquinol
go.drugbank.com/drugs/DB13222ApprovedTilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467]. … In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.